This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 inhibitors ... action, including T-cell activation and proliferation. Although the mechanism ...

progression and reduces all-cause mortality risk compared with dipeptidyl peptidase-4 inhibitors (DPP-4i) in male patients with moderate to severe CKD and type 2 diabetes. GLP1-RA does not appear ...